The Trump administration is requesting federal judges in Texas to dismiss a lawsuit aimed at restricting access to Mifepristone, an abortion drug. This move aligns with the Biden administration’s stance that Texas isn’t the appropriate venue for such lawsuits.
In a filing from the Justice Department, officials noted that Idaho, Missouri, and Kansas have no connection to Texas and argued they weren’t involved in the lawsuit against the Food and Drug Administration regarding the availability of the drug online and via mail.
Major pharmacies are set to begin offering abortion medications.
“This lawsuit aside, the state hasn’t contested that their claims are unrelated to the Northern District of Texas,” the DOJ explained. “The state cannot support the lawsuits which the original plaintiffs are found to be involved. Now, these plaintiffs are voluntarily dismissing their claims, and the state’s allegations are irrelevant to this district.”
Three Republican-led states are challenging FDA actions from 2016 and 2021 that relaxed drug restrictions, which could allow for drug-induced abortions up to 10 weeks into pregnancy, instead of the previous limit of seven weeks. Additionally, there are concerns about the mailing of drugs, as some women may never meet their clinician.
Recent reports indicate a sharp rise in the use of abortion drugs, showing “significant increases.”
The lower court had previously turned down an attempt to overturn Mifepristone’s FDA approval.
“The state can pursue their claims in districts where it’s appropriate,” the federal lawyer asserted. However, this summary highlighted the weak points in the state’s argument, for instance, their challenge to the FDA’s 2016 regulations that allow for pregnancy termination up to 10 weeks instead of just seven.
Last year, the Supreme Court dismissed a lawsuit from anti-abortion doctors and the Medical Association after determining the plaintiff couldn’t demonstrate personal harm from the regulations on pill access.
The Trump administration also indicated that the state’s challenge regarding the FDA’s 2016 decisions was beyond the six-year legal limitation.
